Singular Genomics Systems, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation
Lease incentives received or receivable
Amortization of right-of-use lease assets
Depreciation
Long-lived asset impairment
Accretion of debt issuance costs
Amortization of premium (accretion of discount) on short-term investments
Loss on disposal of property and equipment
Change in fair value of convertible promissory notes
Change in fair value of warrant liability
Changes in operating assets and liabilities:
Accounts receivable
Inventory, net
Prepaid expenses and other current assets
Other noncurrent assets
Accounts payable
Accrued expenses
Other current liabilities
Lease liabilities
Other noncurrent liabilities
Net cash used in operating activities
Investing activities
Purchases of short-term investments
Maturities of shot-term investments
Sales of short-term investments
Purchases of property and equipment
Net cash provided (used) by investing activities
Financing activities
Proceeds from issuance of common stock under employee stock purchase plan
Proceeds from issuance of common stock under equity incentive plans
Repurchases of common stock under equity incentive plans
Proceeds from initial public offering, net of issuance costs
Proceeds from issuance of convertible promisorry notes
Issuance costs in connection with Series B convertible preferred stock
Proceeds from issuance of debt
Repayments of debt principal and issuance costs in connection with refinancing
Net cash provided by financing activities
Net decrease in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash, beginning of year
Cash and cash equivalents and restricted cash, end of period
Supplemental disclosure for cash activities
Interest paid
Supplemental disclosure for non-cash activities
Lease liability recognized upon lease modifications during the period
Inventory transferred to property and equipment
Conversion of convertible promissory notes to common stock
Conversion of preferred stock to common stock
Cashless warrant exercise
Purchases of inventory included in accounts payable
Vesting of common stock issued for early exercise of stock options
Purchase of property plant and equipment included in accounts payable
Purchases of inventory included in accrued expenses
Initial lease liability recognized upon lease commencements during the period
Initial lease liability recognized upon adoption of ASC 842
Reduction of lease liability for lease termination
Noncurrent deposit transferred to property and equipment

Comments